Teva Pharmaceutical Industries Ltd reports $3.98 billion revenue for quarter ended March 31, 2026
Teva Pharmaceutical Industries Ltd reported revenue of $3.98 billion for the quarter ended March 31, 2026.
For the same period it posted net income of $369 million, or $0.31 per diluted share.
That is a net margin of 9.3%.
On Sanad's AAOIFI Standard 21 screen, Teva Pharmaceutical Industries Ltd is currently not compliant: interest-bearing debt is 34% of market capitalisation (limit 30%), and impure income is 1.2% of revenue (limit 5%).
Is Teva Pharmaceutical Industries Ltd halal?
See the full AAOIFI screening of Teva Pharmaceutical Industries Ltd
See the full AAOIFI screening of Teva Pharmaceutical Industries Ltd
Source: 10-Q filed with the U.S. Securities and Exchange Commission on April 29, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.